Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives

Aimee C Hodowanec; Andreas Pikis; Takashi E Komatsu; Mario R Sampson; Islam R Younis; Julian J O'Rear; Mary E Singer

doi:10.1002/jcph.1363

Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives

J Clin Pharmacol. 2019 Jun;59(6):784-798. doi: 10.1002/jcph.1363. Epub 2018 Dec 26.

Authors

Aimee C Hodowanec¹, Andreas Pikis¹, Takashi E Komatsu¹, Mario R Sampson², Islam R Younis², Julian J O'Rear¹, Mary E Singer¹

Affiliations

¹ Center for Drug Evaluation and Research, Office of Antimicrobial Products, Division of Antiviral Products, Food and Drug Administration, Silver Spring, MD, USA.
² Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Clinical Pharmacology, Division of Clinical Pharmacology IV, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 30586161
DOI: 10.1002/jcph.1363

Abstract

This review summarizes the significant impact of cytomegalovirus (CMV) infection on solid organ and hematopoietic stem cell transplant recipients. A discussion of the various CMV prevention and treatment strategies is provided, including a detailed description of each of the available CMV antiviral drugs.

Keywords: antiviral drugs; cytomegalovirus; immunocompromised; infectious diseases; transplantation; viral diseases.

Publication types

Review

MeSH terms

Antiviral Agents / pharmacokinetics
Antiviral Agents / therapeutic use*
Cytomegalovirus Infections / diagnosis
Cytomegalovirus Infections / drug therapy*
Cytomegalovirus Infections / prevention & control*
Drug Resistance, Viral
Drugs, Investigational / therapeutic use
Forecasting
Humans
Transplant Recipients*

Substances

Antiviral Agents
Drugs, Investigational